Preparation method of medicine for treating nephropathy
The preparation of Sparsontan by a 2-step reaction method has solved the problems of long synthesis routes, low yields and difficult to obtain starting materials in the prior art, and achieved high purity, high yields and environmentally friendly production results, reducing the Production cost.
Patent Information
- Application Number
- CN202410964849.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the synthesis route of Sparsontan is relatively long, the yield is low, the starting raw materials are difficult to obtain, and the environmental friendliness is insufficient, so it cannot meet the efficient and low-cost production needs.
Using a 2-step reaction method, the intermediate compound of formula b is prepared by docking reaction of the compound of formula a and 5-amino-3,4-dimethylisoxazole, and then with 2-butyl-3-((4,4,5, ,5-tetramethyl-1,3,2-dioxaborane-2-yl)methyl)-1,3-diazaspiro[4.4]nona-4-one prepared by suzuki reaction Tan, using organic base catalyst and palladium catalyst, the reaction conditions are controlled to obtain a high purity product.
The high purity and high yield preparation of Sparsontan has been achieved, the synthesis route is shortened, the production cost is reduced, and the starting raw materials are easy to obtain and environmentally friendly.
Smart Images

Figure CN118930532A_ABST
Abstract
Description
Field of the Invention
[0001] The invention belongs to the field of chemical medicines, and in particular relates to a method for preparing a medicine for treating kidney disease. Background Art
[0002] Primary immunoglobulin A nephropathy (IgA nephropathy) is a chronic glomerulonephritis characterized by the deposition of large amounts of immunoglobulin A (IgA) in the glomeruli. This disease usually presents with hematuria, proteinuria, and chronic kidney disease. Currently, there are limited methods for treating primary immunoglobulin A nephropathy. As a progressive autoimmune disease of the kidney, the pathogenesis of immunoglobulin A nephropathy (IgA nephropathy) has not yet been clarified. During biochemical testing, the main feature is the deposition of immune complexes (combinations formed after bacteria (antigens) are phagocytosed by the body's immune cells (antibodies), also known as antigen-antibody complexes) mainly composed of immunoglobulin A (IgA) in the glomeruli. Excessive production of hypoglycosylated IgA1 molecules (pathogenic IgA1 molecules) in the body is regarded as a foreign body by the kidneys, triggering an immune response, causing kidney damage and loss of function. IgA nephropathy is an important cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Despite treatment, 15% to 40% of patients develop ESRD within 10 years of diagnosis. Immunoglobulin A (IgA) nephropathy is the primary glomerular disease with the highest incidence rate in the world, with an annual incidence rate of more than 1.5 per 100,000 people. In China, IgA nephropathy accounts for 40% to 50% of primary glomerular diseases. In 2020, the number of patients with immunoglobulin A nephropathy (IgA nephropathy) worldwide was 9.2669 million, including 2.2 million in China; it is estimated that the total number of immunoglobulin A nephropathy (IgA nephropathy) in the world will reach 9.7306 million in 2025, including 2.3 million in China.
[0003] The current standard treatment for patients with immunoglobulin A nephropathy (IgA nephropathy) is to take renin-angiotensin-aldosterone system blockers, mainly including lisinopril and dipyridamole, which are also the main non-biological drugs used to treat IgA nephropathy. Before the launch of sparsentan, there were no specific therapies approved for IgA nephropathy in the world and China at this stage, and no innovative biological drugs were approved for the treatment of IgA nephropathy.
[0004] Sparsentan is an endothelin and angiotensin II receptor antagonist and the first and only non-immunosuppressive therapy approved for the treatment of this disease; sparsentan is indicated for reducing proteinuria levels in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression and have a urine protein-to-creatinine ratio (UPCR) ≥1.5 g / g.
[0005] Sparsentan is a selective S1P1 and S1P5 receptor modulator that works primarily by regulating the migration and localization of lymphocytes. In primary immunoglobulin A nephropathy, abnormal activation of the immune system and inflammatory responses are key factors leading to glomerular damage and disease progression. Sparsentan slows the development of kidney damage by regulating the activity of S1P receptors, reducing the entry of immune cells into the kidneys, and reducing the extent of inflammatory responses. In addition to regulating the immune system, sparsentan may also treat primary immunoglobulin A nephropathy by improving glomerular function. Studies have shown that sparsentan has potential benefits in regulating angiogenesis and vascular permeability. This can reduce immunoglobulin A deposition within the glomeruli and improve glomerular microcirculation, thereby reducing the extent of renal inflammation and damage.
[0006] Spassentan has good safety and tolerability. Its launch provides a new option for the treatment of IgA nephropathy patients and is an important milestone in advancing transformative treatments for IgA nephropathy.
[0007] The chemical name of sparsentan is 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide, CAS number: 254740-64-2. It is a white to off-white powder, almost insoluble in water, and its solubility is pH-dependent. The chemical structure is as follows:
[0008]
[0009] Prior art document patent CN201410045095 reports the synthesis routes 1 and 2 of sparsentan, which are as follows: Route 1:
[0010]
[0011] This route uses 2-(4-halo-3-(chloromethyl)phenyl)acetonitrile, (2-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)phenyl)boronic acid protected by SEM or MEM group, and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials, and synthesizes sparsentan through 7 steps. However, the route is long, and the (2-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)phenyl)boronic acid protected by SEM or MEM group is not easy to purchase, so it still needs to extend the route for preparation, and the overall yield is low.
[0012] Route 2:
[0013]
[0014] This route uses 4-bromo-3-methylbenzoic acid ethyl ester, (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials and synthesizes sparsentan through 7 steps, but the route is long and the yield is low.
[0015] Prior art document patent WO2010135350 reports the synthesis routes 3 and 4 of sparsentan, which are as follows:
[0016] Route 3:
[0017]
[0018] This route uses 1-bromo-2,4-dimethylbenzene, 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonic acid isopropyl ester, 5-amino-3,4-dimethylisoxazole and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials, and synthesizes sparsentan through 6 steps. The route is longer, the material problems are the same as those of route 1, and the yield is lower.
[0019] Route 4:
[0020]
[0021] This route uses 4-bromo-3-(ethoxymethyl)benzoic acid ethyl ester, (2-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)phenyl)boric acid and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials, and prepares sparsentan through a four-step reaction synthesis. The route is short, but the reaction by-products are relatively large and difficult to purify.
[0022] The existing journal document J.Med.Chem.2005,48,171-179 reports the synthetic route 5 of sparsentan, which is as follows:
[0023] Route 5:
[0024]
[0025] Although this route only has three steps of reaction, the starting materials are not easy to obtain and still need to be prepared through multiple steps of reaction, so the overall route is still relatively long. Summary of the invention
[0026] The object of the present invention is to overcome the deficiencies in the prior art and to provide a new method for preparing spassentan, the method comprising:
[0027]
[0028] Step 1, a compound of formula a and 5-amino-3,4-dimethylisoxazole are docked to prepare an intermediate compound of formula b;
[0029] Step 2, the intermediate compound of formula b and 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one are subjected to Suzuki reaction to prepare sparsentan;
[0030] The X group in the compound of formula a is chlorine, bromine or iodine.
[0031] The route of the present invention is different from the synthesis route of sparsentan reported in the prior art documents CN201410045095, WO2010135350 and J.Med.Chem.2005,48,171-179.
[0032] The invention aims to provide a novel method for preparing high-purity sparsentan through two-step reactions. The route uses 4'-halo-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonyl chloride (Formula a), 5-amino-3,4-dimethylisoxazole and 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials, has the advantages of short route, high yield, easy acquisition of starting materials and environmental friendliness.
[0033] The catalyst for the docking reaction in step 1 of the present invention is an organic base, and the organic base is selected from triethylamine, N, N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine (DMAP) or N-methylmorpholine. In the reaction, the molar feed ratio of the compound of formula a, 5-amino-3,4-dimethylisoxazole and the organic base is controlled to be 1:0.9-1.1:1.1-1.5, preferably 1:1:1.2, and the temperature is controlled at a low reaction temperature of 0-10°C and a short reaction time of 1h, which can not only ensure the complete reaction, but also reduce the sulfonamide degradation impurities and the by-products of the reaction of halogenated benzene with primary amines. The unreacted materials and by-products can be removed by simple post-treatment operations to obtain a high-purity intermediate 4'-halogenated-N-(4,5-dimethylisoxazole-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (formula b). In the reaction, the X groups in formula a are different, and the use of different organic bases has little effect on the reaction results.
[0034] Although 4'-halo-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (Formula b) without sulfonamide protection is used to carry out Suzuki reaction with 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one in step 2 of the present invention, the reaction process is not affected. The smooth progress of the reaction is the key to the implementation of the present invention and also the biggest highlight.
[0035] The palladium catalyst of the Suzuki reaction in step 2 of the present invention is selected from tetrakis(triphenylphosphine)palladium(0), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bis(triphenylphosphine)palladium(0), bis(tricyclohexylphosphine)palladium(0), bis(tri-O-toluenephosphine)palladium(0), preferably tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). The inorganic base catalyst is selected from Li2CO3, K3PO4, Na2CO3, K2CO3 or Cs2CO3, preferably Li2CO3 and Na2CO3 with moderate alkalinity, so as to minimize the degradation of the reaction materials and products. The molar feed ratio of compound formula b, 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one, palladium catalyst and inorganic base catalyst is strictly controlled to be 1:0.9-1.1:0.03-0.08:0.9-1.1, preferably 1:1:0.05:1, which can ensure complete reaction and less by-products. After post-treatment and recrystallization from anhydrous ethanol-water mixed solvent, high-purity sparsentan can be obtained. The X group in the structure of the compound of formula b in this reaction slightly affects the reaction process with different halogen activity; the lower the halogen activity, the slightly lower the yield and purity.
[0036] The present invention provides a new route for synthesizing sparsentan with a short route, high yield and high purity. The method has obvious advantages over the prior art documents, can greatly reduce the production cost of sparsentan, and can benefit from it. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 :Process route diagram of the present invention Specific implementation methods
[0039] The technical solutions in the embodiments of the present invention will be described in detail below in conjunction with the embodiments of the present invention. However, the following embodiments are only used to understand the present invention and cannot limit the present invention. The present invention can be implemented in a variety of different ways as defined and covered by the claims.
[0040] The novel synthesis method of sparsentan and the advantages of the method will be further described below in conjunction with Examples 1-6 of the present invention.
[0041] Example 1: Synthesis of 4'-bromo-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0042]
[0043] 4'-Bromo-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonyl chloride (194.8 g, 0.5 mol), 5-amino-3,4-dimethylisoxazole (56.1 g, 0.5 mol) and 1.2 L of tetrahydrofuran were added to a dry three-necked flask, cooled to below 0°C, triethylamine (60.7 g, 0.6 mol) was added, the temperature was controlled at 0-10°C and stirred for 1 h, the reaction was stopped, ethyl acetate 2.0 L and water 1 L were added, stirred and separated, the organic phase was washed with water 1.5 L, 10% sodium bicarbonate solution 1.2 L, water 1.5 L, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was dried to obtain 4'-bromo-N-(4,5-dimethylisoxazole-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (214.1 g, 92%), Ms m / z 465.2(M+1), 1 H NMR (400MHz, CDCl3): δ1.17(t,3H), 2.41-2.47(d,6H), 3.59(q,2H), 4.82(s,2H), 7.64-8.03(m,7H, Ar-H).
[0044] Example 2: Synthesis of 4'-bromo-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0045]
[0046] 4'-Bromo-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonyl chloride (194.8 g, 0.5 mol), 5-amino-3,4-dimethylisoxazole (56.1 g, 0.5 mol) and 1.2 L of tetrahydrofuran were added to a dry three-necked flask, cooled to below 0°C, pyridine (47.5 g, 0.6 mol) was added, the temperature was controlled at 0-10°C and stirred for 1 h, the reaction was stopped, ethyl acetate 2.0 L and water 1 L were added, stirred and separated, the organic phase was then washed with 1.5 L of water, 10% sodium bicarbonate solution 1.2 L, water 1.5, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was dried to obtain 4'-bromo-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (209.4 g, 90%).
[0047] Example 3: Synthesis of 4'-chloro-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0048]
[0049] 4'-Chloro-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonyl chloride (172.6 g, 0.5 mol), 5-amino-3,4-dimethylisoxazole (56.1 g, 0.5 mol) and 1.2 L of tetrahydrofuran were added to a dry three-necked flask, cooled to below 0°C, pyridine (47.5 g, 0.6 mol) was added, the temperature was controlled at 0-10°C and stirred for 1 h, the reaction was stopped, ethyl acetate 2.0 L and water 1 L were added, stirred and separated, the organic phase was then washed with 1.5 L of water, 10% sodium bicarbonate solution 1.2 L, water 1.5, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was dried to obtain 4'-chloro-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (195.7 g, 93%). Ms m / z 421.2(M+1), 1 H NMR (400MHz, CDCl3): δ1.18(t,3H), 2.42-2.49(d,6H), 3.58(q,2H), 4.81(s,2H), 7.66-8.03(m,7H, Ar-H).
[0050] Embodiment 4: the synthesis method 1 of sparsentan
[0051]
[0052] Under argon atmosphere, 4'-bromo-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (Formula bI, 93.1 g, 0.2 mol), 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one (66.9 g, 0.2 mol), tetrakis(triphenylphosphine)palladium(0) (11.6 g, 10 mmol), lithium carbonate (14.8 g, 0.2 mol), 1.2L of dioxane and 300ml of anhydrous ethanol were placed in a dry three-necked flask, and the temperature was controlled at 70-80°C for 16h. The mixture was filtered while hot, and the filtrate was concentrated to remove 2 / 3 of the solvent. The residue was cooled to room temperature, and 1L of water and 1L of dichloromethane were added, and the mixture was stirred and separated. The organic phase was washed with 1L of water, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to dryness under reduced pressure, and 300ml of n-hexane was added to the residue, stirred and dispersed, filtered, and dried. The dried product was recrystallized with anhydrous ethanol-water (1:3) mixed solvent and dried to obtain sparsentan (94.8g, yield 80%) with a purity of 99.3% and Ms m / z 593.3 (M+1). 1 HNMR (400MHz, CDCl3): δ0.91(t,3H),1.06(t,3H),1.38(s,2H),1.64(q,2H),1.83(s,3H),2.01-1.86(m,8H),2.27(s,3H),2.40(t,2H),3.46-3.3 4(m,2H),4.19(q,2H),4.78(q,2H),6.63(bs,1H),7.10(dd,1H),7.26(dd ,1H),7.27(d,1H),7.38(s,1H),7.51(d,1H),7.62(d,1H),8.03(dd,1H).
[0053] Embodiment 5: the synthesis method 2 of sparsentan
[0054]
[0055] Under argon atmosphere, 4'-chloro-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide (Formula bI, 84.0 g, 0.2 mol), 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one (66.9 g, 0.2 mol), tetrakis(triphenylphosphine)palladium(0) (11.6 g, 10 mmol), sodium carbonate (21.2 g, 0.2 mol) were added. , 1.2L of dioxane and 300ml of anhydrous ethanol are placed in a dry three-necked flask, the temperature is controlled at 70-80°C for 16h, filtered while hot, the filtrate is concentrated to remove 2 / 3 of the solvent, the residue is cooled to room temperature, 1L of water and 1L of dichloromethane are added, stirred for separation, the organic phase is washed with 1L of water, dried over anhydrous sodium sulfate, filtered, the filtrate is concentrated to dryness under reduced pressure, 300ml of n-hexane is added to the residue, stirred and dispersed, filtered, and dried; the dried product is recrystallized with anhydrous ethanol-water (1:3) mixed solvent and dried to obtain sparsentan (89.9g, yield 75%) with a purity of 98.9%.
[0056] Compared with the synthetic route of sparsentan reported in the prior art documents, Examples 1-5 of the present invention have a shorter route, a higher total yield, cheap and readily available starting materials, and are environmentally friendly, which is of great significance for the industrialization of sparsentan.
[0057] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a drug for treating kidney disease, characterized in that: The method is: Step 1, a compound of formula a and 5-amino-3,4-dimethylisoxazole are subjected to docking reaction to prepare an intermediate compound of formula b; Step 2, the intermediate compound of formula b and 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one are subjected to Suzuki reaction to prepare sparsentan; The X group in the compound of formula a is chlorine, bromine or iodine.
2. The preparation method according to claim 1, characterized in that: The catalyst for the docking reaction in step 1 is an organic base, which is selected from triethylamine, N,N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine (DMAP) or N-methylmorpholine.
3. The synthesis method according to claims 1 and 2, characterized in that In the docking reaction of step 1, the molar feed ratio of the compound of formula a, 5-amino-3,4-dimethylisoxazole and the organic base is 1:0.9-1.1:1.1-1.5, preferably 1:1:1.
2.
4. The preparation method according to claim 1, characterized in that: The Suzuki reaction in step 2 requires the addition of a palladium catalyst to catalyze the reaction, and the palladium catalyst is selected from tetrakis(triphenylphosphine)palladium(0), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bis(triphenylphosphine)palladium(0), bis(tricyclohexylphosphine)palladium(0), and bis(tri-O-toluenephosphine)palladium(0), preferably tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II).
5. The preparation method according to claims 1 and 4, characterized in that: The Suzuki reaction in step 2 requires the addition of an inorganic base to catalyze the reaction, and the inorganic base catalyst is selected from Li2CO3, K3PO4, Na2CO3, K2CO3 or Cs2CO3, preferably Li2CO3 or Na2CO3.
6. The preparation method according to claims 1, 4 and 5, characterized in that: In the reaction of step 1, the molar feed ratio of compound formula b, 2-butyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one, palladium catalyst and inorganic base catalyst is 1:0.9-1.1:0.03-0.08:0.9-1.1, preferably 1:1:0.05:1.
Citation Information
Cited By
Crystal form of sparsentan as well as preparation method and pharmaceutical composition thereof
CN120289447A
